ONDINE BIOMEDICAL INC. - Results for the year ended 31 December 2025

Ondine Biomedical Inc. reported FY2025 results highlighting a year of focused investment in clinical evidence generation, operational readiness and targeted commercial progress, with revenue increasing 29% to $2.6 million. The webcast centred on Ondine’s pivotal LANTERN Phase 3 study, which enrolled nearly 5,200 patients across 18 hospitals and is designed to support the company’s U.S. regulatory pathway for nasal photodisinfection, with top-line results expected by the end of Spring 2026. Management also discussed the growing body of real-world clinical and health economic evidence supporting Steriwave®, international adoption, manufacturing readiness and preparations for potential U.S. market entry as the company moves toward what it expects to be a pivotal year ahead.